Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has decided to move its psychedelic DMT stroke program into a private company called Algernon NeuroScience. Moreau telling Proactive AGN Neuro will stay private until it has advanced through to the completion of a Phase 2a stroke study in Q4 of the 2023. Following that, the company will consider a potential direct IPO listing onto the NASDAQ.
Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program
